Bicycle therapeutics announces interim bt5528 phase i clinical trial results and preliminary results from ongoing bt8009 phase i clinical trial

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today provided a clinical update of its wholly-owned, next-generation bicycle toxin conjugates (btcs), reporting interim phase i trial results for bt5528 and preliminary findings from the ongoing dose escalation portion of the bt8009 clinical trial. “we are pleased
BCYC Ratings Summary
BCYC Quant Ranking